Durata Therapeutics initiates Phase 3 study of dalbavancin for the treatment of acute bacterial skin and skin structure infections
Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study of its lead product, dalbavancin, a long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.
Targanta Therapeutics Corporation announced today that it has submitted a Marketing Authorization Application to the European Medicines Agency for its lead candidate, oritavancin, a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal activity against a broad spectrum of gram-positive bacteria.